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Abstract
Background: Compromised epithelial barriers are found in dysplastic tissue of the gastrointestinal tract. Claudins
are transmembrane proteins important for tight junctions. Claudins regulate the paracellular transport and are
crucial for maintaining a functional epithelial barrier. Down-regulation of the oncogenic serine protease, matriptase,
induces leakiness in epithelial barriers both in vivo and in vitro. We found in an in-silico search tight co-regulation
between matriptase and claudin-7 expression. We have previously shown that the matriptase expression level
decreases during colorectal carcinogenesis. In the present study we investigated whether claudin-7 expression is
likewise decreased during colorectal carcinogenesis, thereby causing or contributing to the compromised epithelial
leakiness of dysplastic tissue.
Methods: The mRNA level of claudin-7 (CLDN7) was determined in samples from 18 healthy individuals, 100
individuals with dysplasia and 121 colorectal cancer patients using quantitative real time RT-PCR. In addition,
immunohistochemical stainings were performed on colorectal adenomas and carcinomas, to confirm the mRNA
findings.
Results: A 2.7-fold reduction in the claudin-7 mRNA level was found when comparing the biopsies from healthy
individuals with the biopsies of carcinomas (p < 0.001). Reductions in the claudin-7 mRNA levels were also
detected in mild/moderate dysplasia (p < 0.001), severe dysplasia (p < 0.01) and carcinomas (p < 0.01), compared
to a control sample from the same individual. The decrease at mRNA level was confirmed at the protein level by
immunohistochemical stainings.
Conclusions: Our results show that the claudin-7 mRNA level is decreased already as an early event in colorectal
carcinogenesis, probably contributing to the compromised epithelial barrier in adenomas.
Background
DNA damage promotes carcinogenesis. This is clearly
seen when DNA repair mechanisms are compromised.
The eukaryotic cell takes many measures to prevent
DNA damage, including formation of physical barriers
to prevent the entry of carcinogens and other substances
into the organism. In the gastrointestinal tract, a layer of
polarised epithelial cells, held together by tight junctions
and covered by a layer of mucus, forms a surprisingly
efficient barrier. However, this barrier is often compro-
mised already in dysplastic tissue [1]. This is likely to be
a factor driving carcinogenesis by allowing carcinogens
to enter the underlying tissue.
In the intestine, molecules may pass the monolayer of
epithelial cells, either by the transcellular route involving
transcytosis or by the paracellular route crossing the
tight junctions. Tight junctions are primarily located at
the apical end of the lateral plasma membrane [2]. In
addition to controlling the paracellular diffusion, tight
junctions prevent the diffusion of membrane proteins
and lipids between the apical and the basolateral plasma
membrane domains [3]. Tight junctions are formed
mainly by three types of integral proteins: occludins,
junctional adhesion molecules and claudins [4]. In total,
24 different mammalian claudins have been described
[5]. The composition of claudins in the tight junction
complex is thought to dictate the permeability of the
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junctions [4,6]. The expression levels of various claudins
in a tissue can change according to physiological and
pathological conditions, thereby altering the permeability
of the epithelial barrier [7].
Connections of tight junctions between cells are made
by interactions between the extracellular loops of the
claudins. However, the molecular mechanisms and the
exact stoichiometry behind the assembly of tight junc-
tions are poorly understood [8]. The majority of clau-
dins are known to increase the epithelial tightness by
sealing the tight junctions. Claudins like claudin-1, -4,
-5, -7, -8, -11, -14, and -19 are considered sealing clau-
dins, as increased expression of these leads to increased
epithelial tightness [6,9-12]. Other claudins are able to
form paracellular anion- and cation pores as well as
water channels [5,13]. Claudin-2, -10, and -16 are exam-
ples of pore-forming claudins known to decrease epithe-
lial tightness when expression is increased.
The serine protease matriptase plays an important but,
as yet, poorly defined role in the generation and mainte-
nance of epithelial barriers. Matriptase, encoded by the
ST14 gene, is expressed in most epithelial cells [14] and
its proteolytic activity is tightly regulated by at least two
membrane-bound inhibitors, HAI-1 (SPINT1)a n dH A I -
2( SPINT2)[ 1 5 - 1 7 ] .A b l a t i o no ft h eST14 gene in mice
generates a phenotype with compromised epithelial bar-
rier function and fatal outcome [18,19]. In addition, dys-
regulated matriptase expression as investigated in
transgenic mice has been shown to have a very strong
oncogenic potential [15]. A study using the colonic ade-
nocarcinoma cell line Caco-2, which spontaneously form
tight monolayers of polarized cells, when grown on fil-
ters, showed that siRNA-induced down-regulation of
matriptase resulted in compromised epithelial barrier
function [20].
We have previously shown that the mRNA level of
matriptase and its inhibitors are significantly down-
regulated during colorectal carcinogenesis [21,22]. Still,
the molecular mechanism whereby the proteolytic activ-
ity of matriptase affects the epithelial barrier is
unknown. In the search for downstream effectors of
matriptase, we made an in-silico array based study to
identify genes co-regulated with the matriptase gene,
ST14. The analysis showed that besides the already
known inhibitor of matriptase, HAI-1 encoded by
SPINT1, CLDN7,e n c o d i n gclaudin-7,i st h eg e n em o s t
tightly co-regulated with the ST14 gene. Claudin-7
belongs to the class of claudins promoting epithelial
tightness [10-12] and is found in most epithelia, for
instance in the airways [23], the intestines [24,25], the
Loop of Henle and the collecting duct of the kidney [8].
Claudin-7 is involved in regulation of the permeability
of Cl
- and Na
+ ions. Recently, claudin-7 knockout mice
were generated and shown to have a normal phenotype
at birth. However, within days they developed chronic
dehydration, leading to a fatal outcome 12 days after
birth [12].
In the present study, we investigated the levels of
claudin-7 mRNA during colorectal carcinogenesis and
found that claudin-7 mRNA is significantly decreased in
mild/moderate dysplasia, severe dysplasia and carcino-
matous tissue. The decrease in claudin-7 level could
also be confirmed at the protein level.
Methods
In-silico co-expression array database study
The COXPRESSdb version 4.0 located at http://
coxpresdb.jp/[26] was used to identify genes co-regu-
lated with matriptase. All expression data for this data-
base are based on affymetrix GeneChip, information
which has been released by NCBI GEO. The analysis
was performed using default settings entering ST14 as
gene symbol in the gene search tool. In the results, the
ST14 icon under the human gene search was selected.
Expression similarity for ST14 in relation to all other
genes in the database was calculated using Pearson’s
correlation coefficient and ranked. The opposite correla-
tion coefficients where also calculated and ranked. To
evaluate the strength of co-expression a mutual ranking
(MR) value was calculated using the formula MR(AB) =
(rank(A®B)*r a n k (B®A))
0.5. The lower the MR value the
higher the co-expression.
Human tissue samples
The tissues used in this study have previously been
described [22]. In short, the KAM cohort is based on a
screening performed in the Norwegian Colorectal Can-
cer Prevention study (NORCCAP) in the county of
Telemark, Norway [27] with the ID number
NCT00119912 at Clinicaltrials.gov. In addition, a series
of colorectal cancer (CRC) cases was recruited to the
cohort from Telemark Hospital in Skien and Ulleval
University Hospital in Oslo. The KAM study is
approved by the Regional Committee for Medical
Research Ethics and the Norwegian Data Inspectorate.
In the present study, we analysed 121 cases with carci-
noma, 100 cases with adenomas and 18 healthy indivi-
duals. From individuals with adenomas, control tissue
was sampled 30 cm above the anus. From patients with
carcinomas, two control samples were taken from the
surgically removed specimen. One sample was taken
adjacent to the cancer (normal adjacent) and the other
sample was taken as distant from the cancer as possible
(normal distant). The histology of the adenomas was
examined independently by two histopathologists, who
categorised the degree of dysplasia as either mild/mod-
erate (n = 87) or severe (n = 13). Consensus was
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fied as either low- or high-risk according to the size
and/or differentiation state of the adenoma. A high-risk
adenoma is defined as an adenoma measuring ≥ 10 mm
in diameter and/or with villous components or showing
severe dysplasia [27]. Carcinomas were classified accord-
ing to Dukes staging. The distribution of gender and age
among individuals included in the study is shown in
Table 1.
Real-time reverse transcriptase polymerase chain reaction
The tissue samples were frozen as soon as possible after
surgery and stored in liquid nitrogen until RNA purifi-
cation. Total RNA was purified from tissue as recom-
mended by the manufacturer using E.Z.N.A. Total RNA
Kit II (cat. no. R6834-02, Omega Bio-Tek) and the
RNase Free DNase kit I (cat. no. E1091-01). cDNA
synthesis was performed on approximately 200 ng RNA
per 20 μl using the High-Capacity cDNA Archive Kit
(cat. no. 4375222, Applied Biosystems). Quantitative real
time RT-PCR for claudin-7 was performed on the
ABI7300 sequence detection system (Applied Biosys-
tems) in Universal PCR Master Mix (cat. no. 4326614,
Applied Biosystems) using 250 nM probe and 300 nM
primers. Primers and probe were: CLDN7 forward
5’-ATGATGAGCTGCAAAATGTACGA-3’; CLDN7
reverse 5’-GCACCAGGGAGACCACCAT-3’; CLDN7
probe 5’- FAM-CGCCCTGTCCGCGGCCTT-BHQ-3’.
Primers were designed within different exons and with
the probe covering the border of exon 1 and exon 2 to
prevent amplification of genomic DNA. Primers and
probes were obtained from TAGCopenhagen (Denmark).
The endogenous b-actin control was obtained pre-devel-
oped (cat. no.4310881E) from Applied Biosystems. In a
validation experiment using a control sample, a dilution
series was assayed by the comparative Ct method [28].
When Ct values were plotted against the logarithmic
value of the amount of cDNA added, it was shown that
the assays were quantitative over a range of 4096-fold
dilution and that the PCR reactions had similar efficien-
cies provided that a threshold of 0.1 is used for claudin-7
and 0.175 is used for b-actin.T h et h r e s h o l di saf i x e d
fluorescence signal level above the baseline and the Ct
value of a sample is determined as the fractional cycle
number where the sample’s fluorescence signal exceeds
the threshold. All samples were quantified in triplicates.
The standard deviation on the triplicates was 6% or less.
The standard deviation on repeated measurements of the
same sample (the control) in separate experiments was
26%, indicating the day-to-day variation of the assay.
Negative controls (where the RNA was not converted
into cDNA) and positive controls were included in all
runs. Samples for which either the b-actin or claudin-7
values fell outside the upper or lower limits of the stan-
dard curve were excluded from the study.
Western blot analysis
25-50 mg of frozen tissue was lysed in 500 μlP B Sc o n -
taining 1% Triton X-100, 0.5% deoxycholate, and pro-
tease inhibitors (10 mg/l benzamidine, 2 mg/l pepstatin
A, 2 mg/l leupeptin, 2 mg/l antipain, and 2 mg/l chy-
mostatin). Protein concentrations were measured using
BCA™ Protein Assay Kit (cat. no. 23225, Pierce). Sam-
ples were mixed with 2 × SDS PAGE sample buffer con-
taining DTT and boiled for 5 min. The proteins were
resolved on 7% acrylamide gels and transferred to
Immobilon-P PVDF membranes (Millipore cat. no.
IPVH00010). The blots were blocked with 10% non-fat
dry milk in PBS containing 0.1% Tween-20 (PBST).
PVDF membranes were probed with 0.5 μg/ml rabbit
anti-claudin-7 antibody (cat. no. 34-9100, Invitrogen) in
1% non-fat dry milk in PBST at 4°C overnight. Mem-
branes were washed 3 × 5 min wash with PBST and
incubated 1 hour with 2 ng/ml goat anti-rabbit second-
ary antibody conjugated with horseradish peroxidase
(HRP) (cat no. 1858415, Pierce) diluted in 1% non-fat
dry milk in PBST. After 3 × 5 min wash with PBST the
signal was developed using the ECL reagent Supersignal
West Femto Maximum Sensitivity Substrate (cat. no.
34095, Pierce) according to the protocol supplied by the
manufacturer, and developed with a Fuji LAS1000-
camera (FujiFilm, Sweden). Blots were stripped in 5 ml
Restore™ Western Blot Stripping Buffer (cat. no. 21059,
Pierce) for 15 min at 37°C. The above mentioned
Table 1 Characteristics of cases and healthy individuals participating in this study
Healthy
individuals
Individuals with mild/moderate
dysplasia
Individuals with severe
dysplasia
Individuals with
carcinomas
Total number of individuals in
the study
(n = 18) (n = 87) (n = 13 ) (n = 121)
Number of men 6 61 7 66
Number of women 12 26 6 55
Mean age ± S.D. 56.8 ± 4.5 56.9 ± 3.6 54.9 ± 3.1 69.5 ± 12.0
Comparing the group of healthy individuals with the other groups showed that there were significantly more males in the group with mild dysplasia and CRC
(p < 0.001; Chi Squared test). The mean age is significantly higher among patients with CRC compared to the three other groups (p < 0.001; Kruskal-Wallis and
Dunn’s Multiple Comparison test).
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body against ß-actin (cat. no. 8226, Abcam) for one
hour at room temperature and 2 ng/ml goat anti-mouse
secondary antibody conjugated with HRP (cat. no.
1858413, Pierce) for one hour.
Immunohistochemistry
Paraformaldehyde-fixed, paraffin-embedded tissue sec-
tions were used for the immunohistochemical analysis.
The sections were deparaffinated and antigen retrieval
was performed in 10 mM Tris, 0.5 mM EGTA, and pH
9 by microwave treatment for 18 min at 600 Watt. Sub-
sequently, after cooling for 20 min they were rinsed
with distilled water. The sections were then treated with
3% H2O2 in distilled water for 10 min and rinsed thor-
oughly in distilled water, washed in TBS buffer pH 7.6
for 5 min before a 10 min incubation with 1% BSA
diluted in TBS buffer. Subsequently, the sections were
incubated at room temperature in rabbit anti-claudin-7
antibody (cat. no. 34-9100, Invitrogen) 2 μg/ml in 1%
BSA in TBS buffer for 60 min. The sections were then
washed 3 × 5 min in TBS buffer, before visualization in
EnVision™+ System HRP/rabbit (cat. no. K-4011,
DAKO) for 30 min. After an additional 3 × 5 min wash
in TBS buffer, DAB (cat. no. K-4011, DAKO) was
applied for 10 min. The slides were then rinsed in dis-
tilled water and counterstained with Mayer’s Haematox-
ylin for 90 sec and rinsed in water for 5 min before
dehydration and mounting in Pertex™ Mounting
Medium (cat. no. 00801, Histolab).
Statistical analysis
GraphPad Prism 4 was used for the statistic calculations.
The data were not adjusted for gender since the inci-
dence ratio of CRC between the genders is 1:1 in Norway.
For all statistical analysis the data was log transformed.
Kruskal Wallis and Dunn’s Multiple Comparison test
were used for statistical comparison of samples from
healthy individuals, samples of mild/moderate dysplasias,
severe dysplasias and CRC samples. Paired Student’st -
test was used for comparison of affected tissue with the
matching control sample.
Results
In-silico analysis of genes co-expressed with the
matriptase gene, ST14
In order to identify genes co-regulated with the ST14
gene, encoding matriptase, an in-silico analysis was per-
formed. The analysis, performed on COXPRESSdb ver-
sion 4.0 database, shows a network of co-expressed
genes including the ST14 gene (Figure 1). Many of these
genes are already known to be either inhibitors or sub-
strates of matriptase, such as SPINT1 and SPINT2,
encoding the inhibitors of matriptase, HAI-1 and HAI-2
respectively, and the PRSS8 gene encoding the matrip-
tase substrate, prostasin. ST14 has the highest degree of
co-regulation with its inhibitor SPINT1 (correlation
coefficient = 0.70 (Pearson’s) and a MR = 2.0). In addi-
tion to these previously described molecules in the
matriptase pathway, we found a new gene, CLDN7,t h a t
encodes claudin-7 (correlation coefficient = 0.69 and
MR = 2.8) to be co-regulated with the ST14 gene.
Moreover, the analysis showed that claudin-7 and
matriptase have conserved co-expression between
human and mouse orthologs. As claudin-7 is involved in
the regulation of the epithelial permeability, we found it
plausible that the increased epithelial leakiness observed
during carcinogenesis could be mediated through a
decreased level of claudin-7.
Expression of claudin-7 mRNA during carcinogenesis
The mRNA levels of claudin-7 were measured by quan-
titative real-time RT-PCR. We successfully measured
claudin-7 mRNA in 15 biopsies from normal mucosa in
healthy individuals, in 84 mild/moderate dysplasias with
82 corresponding control samples, 13 severe dysplasias
with 11 corresponding control samples, and in 102 colo-
nic carcinomas with 82 corresponding distant and 93
corresponding adjacent control samples (Figure 2 and
Table 2).
In general, our analysis showed that the claudin-7
mRNA levels were decreased as an early event in the
carcinogenesis, as the claudin-7 mRNA level is
decreased already in the mild/moderate dysplasias. The
decrease was maintained in the severe dysplasias and
the carcinomas. The levels of claudin-7 mRNA in
ST14 CLDN7 ELF3
CLDN4
BIK CLDN3
MYO5B
KRTCAP3
TMC4
RAB25
PRSS8
AP1M2
SPINT1
ARHGEF5
JUP
SERINC2
HOOK2
SPINT2
LSR
BAIAP2L1
MAPK13
Figure 1 In-silico analysis showing the ST14 co-expressed gene
network. The figure shows a modified version of the analysis
performed using the COXPRESdb version 4.0 http://coxpresdb.jp/.
Each gene is represented by a node. Lines between nodes indicate
co-expression. The genes with direct ST14 co-expression are marked
with a line to the ST14 node. These genes are SPINT1 (encoding
HAI-1), CLDN7 (encoding claudin-7), LSR (encoding lipolysis
stimulated lipoprotein receptor) and MAPK13 (encoding mitogen-
activated protein kinase 13). Bold lines indicate a mutual ratio (MR)
below 5 and normal lines indicate a MR between 5 and 30.
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nomas were not affected (Table 2). A highly significant
2.7-fold reduction in the claudin-7 mRNA level was
found, when comparing the biopsies from healthy indivi-
d u a l sw i t ht h es a m p l e so fc a r c i n o m a s( p<0 . 0 0 1 ,
Kruskal Wallis and Dunn’s Multiple Comparison test).
Comparing affected and normal tissue from the CRC
patients using Paired Student’st - t e s ts h o w e da2 . 0 - f o l d
reduction (95% confidence interval (CI): 1.4-2.9) and a
1.7-fold reduction (CI: 1.2-2.5) in expression level for
Figure 2 Claudin-7 mRNA levels in healthy individuals, individuals with dysplasia and individuals with carcinomas as determined by
real-time RT-PCR. Samples from healthy individuals (cross), normal (open circle) and affected tissue (filled circle) from individuals with mild/
moderate dysplasia, normal (open square) and affected tissue (filled square) from individuals with severe dysplasia, normal adjacent (open
triangle), normal distant (open triangle) and carcinomatous tissue (filled diamond) from colorectal cancer patients were analysed for claudin-7
mRNA levels relative to the b-actin mRNA levels. The horizontal line represents the mean values. The p-value indicated with a ¤ is calculated
using Kruskal Wallis and Dunn’s Multiple Comparison test and p-values marked with a * are calculated using Paired Student’s t-test.
Table 2 Claudin-7 mRNA levels in normal and affected tissues normalised to the b-actin mRNA level
Variable mRNA level in normal tissue
Mean ± S.D.
P
a mRNA level in adenomas/carcinomas
Mean ± S.D.
P
a P
b
Healthy individuals 1.19 ± 0.70
Individuals with mild/moderate dysplasia 1.24 ± 0.67 NS 0.84 ± 0.58 NS <0.001
Individuals with severe dysplasia 1.34 ± 0.75 NS 0.87 ± 0.69 NS <0.01
Cancer patients 0.82 ± 0.73 (distant)
0.83 ± 0.66 (adjacent)
NS
NS
0.44 ± 0.48
“
<0.001 <0.01
<0.001
NS = not significant.
a) p value for the comparison to the expression levels in tissue from healthy individuals using Kruskal Wallis and Dunn’s Multiple Comparison test.
b) p value for the comparison of the expression levels in normal and affected tissue from the same individual using Paired Student’s t-test.
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0.01) samples, respectively. A similar analysis on indivi-
duals with mild/moderate or severe dysplasia showed a
1.6-fold (CI: 1.4-1.9; p < 0.001) and a 1.5-fold (CI: 1.2-
1.9; p < 0.01) reduction in the claudin-7 mRNA levels,
respectively. We found no correlation between the clau-
din-7 mRNA levels and age, gender, high risk/low risk
status of the adenoma, or Duke’s stage of the carcinoma
(data not shown).
Expression and localisation of claudin-7 protein in
colorectal cancers
C a r c i n o m at i s s u ea n dn o r m a lm u c o s af r o mf i v eC R C
patients were extracted and the proteins were analysed
on Western blots (Figure 3). Only one distinct band of
approximately 22 kDa was detected using an antibody
against claudin-7. This is in accordance with the
expected size of claudin-7 [29]. Immunohistochemical
stainings were performed on adenomas from four indi-
viduals without any history of carcinomas and on CRC
tissue and normal mucosa from five CRC patients
(Figure 4 and additional files 1). All stainings of adeno-
mas showed essentially the same, and a representative
example is shown in Figure 4. An intense claudin-7
reaction was seen in histologically normal appearing
mucosa (Figure 4B and 4C) whereas dysplastic tissue
ranged from almost no staining to staining similar to
the normal mucosa (Figure 4B and 4D). Stainings of
the five colorectal cancer samples also showed essen-
tially the same and is shown in figure 4 and additional
file 2. Histologically normal mucosa from cancer
patients also displayed an intense claudin-7 reaction
that was detected from the transitional zone (Figure 4F
and 4G). In the cancerous tissue, the staining was
reduced or almost absent (Figure 4F and 4H). These
observations are consistent with the claudin-7 mRNA
levels obtained in this study. The normal appearing
mucosa from the transitional zone showed, at high
magnification, staining for claudin-7. The staining was
mainly localised at the basolateral plasma membranes
of the surface epithelial cells (Figure 4C and 4G),
whereas the ademomatous and carcinomatous tissue
showed faint, patchy staining of the epithelial strands
of tumor tissue (Figure 4B and 4F).
Discussion
In the present study we found a correlation between the
claudin-7 mRNA level, as determined by real-time RT-
PCR, and the claudin-7 protein level, as determined by
immunohistochemistry in normal mucosa, adenomas
and carcinomas of the colon. This suggests that clau-
din-7 mRNA level reflects the protein level. Our results
suggest that a decrease in the level of claudin-7 occurs
already in mild/moderate dysplasias as an early event in
carcinogenesis and that the decreased level is main-
tained in severe dysplasias and in the CRC tissue. To
our knowledge this is the first analysis of claudin-7
mRNA expression in colorectal mucosa from healthy
individuals and from individuals with colorectal dyspla-
sia. Previous studies have compared normal and cancer-
ous colorectal tissue from the same individual. The
group of Nakayama et al. [24] found a lower expression
of claudin-7 in 80% of invasive CRCs (n = 90) than in
non-neoplastic tissue, which corresponds well with our
findings. However, our observations are in contrast to
the studies by Kuhn et al. [25] and Darido et al. [30],
who both found higher expression of claudin-7 protein
in CRC tissue as compared to normal tissue from the
same individual, using immunohistochemistry alone.
For other types of cancer, a number of studies have
compared claudin-7 expression in malignant tissue and
normal tissue from patients. They find that claudin-7 is
down-regulated in head and neck cancer [31], nasophar-
yngeal cancer [32], squamous cell carcinomas of the
oesophagus [33] and in breast cancer [29,34,35]. How-
ever, claudin-7 seems to be up-regulated in gastric can-
cer [36] and ovarian cancer [37]. In squamous cell
carcinomas of the oesophagus, reduced expression of
claudin-7 correlates with invasion and metastasis [33].
claudin-7
β-actin
Normal adjacent 
Normal distant 
 CRC
17 kDa
26 kDa
34 kDa
43 kDa
55 kDa
72 kDa
Figure 3 Western blot detecting claudin-7 and ß-actin.T h e
upper panel shows claudin-7 in samples from a colorectal cancer
patient. Normal distant is a sample taken as far away from the
tumour as possible in the surgically removed tissue. Normal
adjacent is a sample taken just adjacent to the tumour and CRC is
from the cancer itself. The lower panel shows the loading control
(ß-actin).
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Figure 4 Immunohistochemical staining for claudin-7 in colorectal adenomas, carcinomas and adjacent normal tissue. The top four
pictures are taken from an individual with dysplasia but no record of carcinoma and the bottom four pictures are from a patient with colorectal
cancer. A) Tissue section including both normal mucosa and dysplastic tissue, stained with PAS/Alcian. B) Neighbouring tissue section stained for
claudin-7. The white arrow indicates mucosa of normal appearance and the black arrow indicates dysplastic tissue. C) High magnification of the
normal mucosa from B, showing staining mainly at the basolateral cell membranes of the epithelial cells. D) High magnification of the dysplastic
tissue from B showing a patchy staining pattern with areas of low and normal staining. E) Tissue section with cancerous tissue to the right and
normal mucosa to the left, stained with Hematoxylin and Eosin. F) Neighbouring tissue section stained for claudin-7. The white arrow indicates
the mucosa with normal appearance. The black arrow points out carcinomatous tissue. G) High magnification of histologically normally
appearing mucosa from F, showing staining mainly localised to the basolateral cell membranes of the surface epithelial cells. H) High
magnification of carcinomatous tissue showing faint, patchy staining of the epithelial strands of tumour tissue. Scale bars: 500 μm( A+B+E+
F), 100 μm (C + D + G + H).
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histological grading of breast carcinomas [29,34].
Our in-silico analysis suggests that dysregulated
matriptase may affect the epithelial tightness during
carcinogenesis by modulating the expression of clau-
din-7. We have previously shown that the mRNA
expression levels of matriptase (ST14) and HAI-1
(SPINT1) are dysregulated during colorectal carcino-
genesis in a cohort very similar to the one used in this
study [21,22]. Comparison between the mRNA levels
of claudin-7 (this study) and matriptase mRNA levels
in the similar cohort [21] shows that they have a vir-
tually identical pattern, confirming that mRNA
expression of matriptase and claudin-7 are closely
correlated.
This suggests that the genes encoding matriptase and
claudin-7 m a yb er e g u l a t e db yt h es a m et r a n s c r i p t i o n
factors. Alternatively, the expression levels of matriptase
may affect the expression levels of claudin-7. We
attempted to analyse whether an over-expression of
matriptase in the colonic adenocarcinoma cell line
Caco-2 influenced the claudin-7 mRNA level. However,
these experiments were inconclusive as manipulation of
matriptase expression is cytotoxic (Vogel et al., unpub-
lished results). Further investigations are needed to clar-
ify this point.
It has recently been shown that siRNA silencing of
matriptase in Caco-2 cells resulted in up-regulation of
the claudin-2 protein level [20]. Claudin-2 is a pore-
forming claudin closely related to claudin-7 [38].
Up-regulation of claudin-2 thus results in increased
epithelial leakiness. Claudin-2 is heavily up-regulated
in colorectal cancer tissue compared to normal tissue
from the same individual [39,40]. There have been no
reports about the expression level of claudin-2 in dys-
plastic tissue. The increased epithelial permeability
seen in colorectal dysplastic tissue is thus probably the
result of dysregulation of a number of claudins, some
of which may depend on matriptase expression or
activity.
In esophageal squamous cell carcinoma cells, over-
expression of claudin-7 resulted in more adhesive and
less invasive cells, whereas knockdown of claudin-7
using a small interfering RNA approach led to enhanced
invasion into a three-dimensional matrix [41]. This sug-
gests that claudin-7 down-regulation does indeed contri-
bute to drive carcinogenesis.
Conclusions
In conclusion, the present study shows that the level of
claudin-7 is decreased as an early event in colorectal
carcinogenesis and may play a role by decreasing epithe-
lial tightness, thereby allowing carcinogens to enter the
tissue.
Additional material
Additional file 1: Immunohistochemical staining for claudin-7 in
dysplastic tissue. The figure shows sections from three individuals with
dysplasias. Each individual is represented in the rows marked with the
numbers id#62, id#488 and id#536. The left column shows an area in the
biopsy with mucosa of normal histological appearance, whereas the right
column shows an area of dysplasia. Scalebars: 100 μm.
Additional file 2: Immunohistochemical staining for claudin-7 in
colorectal cancer. The figure represents colorectal cancer sections from
four patients. Each individual is represented in the rows marked with the
numbers patient A, patient C, patient D and patient O. The left column
shows an area in the biopsy with mucosa of normal histological
appearance, whereas the right column shows an area of cancerous
tissue. Scalebars: 100 μm.
Acknowledgements
We thank Christel Halberg for kind technical help and assistance performing
the mRNA analysis and Margit Bæksted for performing the
immunohistochemical stainings. This work was supported by The Norwegian
Cancer Society, Telemark University College, the Norwegian Colorectal
Cancer Prevention (NORCCAP) study, Eastern Norway Regional Health
Authority, The Cluster of Cell Biology at the University of Copenhagen, The
Harboe Foundation, The Augustinus Foundation, The Brothers Hartmanns
Foundation, The A.P. Møllers Foundation for the Advancement of Medical
Science and the Lundbeck Foundation.
Author details
1Department of Cellular and Molecular Medicine, Faculty of Health Science,
University of Copenhagen, Denmark.
2Department of Biology, Faculty of
Science, University of Copenhagen, Copenhagen, Denmark.
3Department of
Medical Anatomy, Faculty of Health Science, University of Copenhagen,
Copenhagen, Denmark.
4Department of Pathology, Diagnostic Center,
Copenhagen University Hospital, Copenhagen, Denmark.
5Department of
Pathology, Oslo University Hospital, Oslo, Norway.
6Department of Oncology,
Oslo University Hospital, Oslo, Norway.
7Department of Gastroenterological
Surgery Oslo University Hospital, Oslo, Norway.
8Faculty of Medicine,
University of Oslo, Oslo, Norway.
9Department of Genetics, Institute for
Cancer Research, Oslo University Hospital, Oslo, Norway.
10Department of
Environmental and Health Studies, Telemark University College, Bø, Norway.
Authors’ contributions
SF and LV conceived the idea of the study. SF performed the in-silico
analysis. EHK, IMBL, EJ, TI and KMT established the NORCCAP and Ulleval
colorectal cancer cohort (KAM cohort). LV and EHK extracted the RNA. LV
validated primers and probes. JB did the western blotting. ESR performed
the immunohistochemical stainings. SSP took the pictures. IMBL performed
and evaluated the sections of immunohistochemical analysis. JB analysed
the data, prepared the figures and performed the statistical analysis. JB
drafted the first manuscript. All authors helped with the draft, read and
approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 27 September 2010 Accepted: 10 February 2011
Published: 10 February 2011
References
1. Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM: Increased
tight junctional permeability is associated with the development of
colon cancer. Carcinogenesis 1999, 20:1425-1431.
2. Angelow S, Ahlstrom R, Yu AS: Biology of claudins. Am J Physiol Renal
Physiol 2008, 295:F867-F876.
3. Martin TA, Jiang WG: Loss of tight junction barrier function and its role in
cancer metastasis. Biochim Biophys Acta 2009, 1788:872-891.
4. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE: Tight junction
proteins. Prog Biophys Mol Biol 2003, 81:1-44.
Bornholdt et al. BMC Cancer 2011, 11:65
http://www.biomedcentral.com/1471-2407/11/65
Page 8 of 95. Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat
Rev Mol Cell Biol 2001, 2:285-293.
6. Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE: Structure
and function of claudins. Biochim Biophys Acta 2008, 1778:631-645.
7. Ouban A, Ahmed AA: Claudins in human cancer: a review. Histol
Histopathol 2010, 25:83-90.
8. Will C, Fromm M, Muller D: Claudin tight junction proteins: novel aspects
in paracellular transport. Perit Dial Int 2008, 28:577-584.
9. Oliveira SS, Morgado-Diaz JA: Claudins: multifunctional players in
epithelial tight junctions and their role in cancer. Cell Mol Life Sci 2007,
64:17-28.
10. Hou J, Gomes AS, Paul DL, Goodenough DA: Study of claudin function by
RNA interference. J Biol Chem 2006, 281:36117-36123.
11. Alexandre MD, Jeansonne BG, Renegar RH, Tatum R, Chen YH: The first
extracellular domain of claudin-7 affects paracellular Cl- permeability.
Biochem Biophys Res Commun 2007, 357:87-91.
12. Tatum R, Zhang Y, Salleng K, Lu Z, Lin JJ, Lu Q, et al: Renal salt wasting
and chronic dehydration in claudin-7-deficient mice. Am J Physiol Renal
Physiol 2010, 298:F24-F34.
13. Rosenthal R, Milatz S, Krug SM, Oelrich B, Schulzke JD, Amasheh S, et al:
Claudin-2, a component of the tight junction, forms a paracellular water
channel. J Cell Sci 2010, 123:1913-1921.
14. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH: Delineation of
matriptase protein expression by enzymatic gene trapping suggests
diverging roles in barrier function, hair formation, and squamous cell
carcinogenesis. American Journal of Pathology 2006, 168:1513-1525.
15. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, et al:
Deregulated matriptase causes ras-independent multistage
carcinogenesis and promotes ras-mediated malignant transformation.
Genes Dev 2005, 19:1934-1950.
16. Szabo R, Hobson JP, Christoph K, Kosa P, List K, Bugge TH: Regulation of
cell surface protease matriptase by HAI2 is essential for placental
development, neural tube closure and embryonic survival in mice.
Development 2009, 136:2653-2663.
17. Szabo R, Molinolo A, List K, Bugge TH: Matriptase inhibition by hepatocyte
growth factor activator inhibitor-1 is essential for placental
development. Oncogene 2007, 26:1546-1556.
18. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, et al:
Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier
function, hair follicle development and thymic homeostasis. Oncogene
2002, 21:3765-3779.
19. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, et al: Epithelial
integrity is maintained by a matriptase-dependent proteolytic pathway.
Am J Pathol 2009, 175:1453-1463.
20. Buzza MS, Netzel-Arnett S, Shea-Donohue T, Zhao A, Lin CY, List K, et al:
Membrane-anchored serine protease matriptase regulates epithelial
barrier formation and permeability in the intestine. Proc Natl Acad Sci
USA 2010, 107:4200-4205.
21. Vogel LK, Saebo M, Skjelbred CF, Abell K, Pedersen ED, Vogel U, et al: The
ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas
and carcinomas than corresponding tissue from control individuals. BMC
Cancer 2006, 6:176.
22. Selzer-Plon J, Bornholdt J, Friis S, Bisgaard HC, Lothe IM, Tveit KM, et al:
Expression of prostasin and its inhibitors during colorectal cancer
carcinogenesis. BMC Cancer 2009, 9:201.
23. Coyne CB, Gambling TM, Boucher RC, Carson JL, Johnson LG: Role of
claudin interactions in airway tight junctional permeability. Am J Physiol
Lung Cell Mol Physiol 2003, 285:L1166-L1178.
24. Nakayama F, Semba S, Usami Y, Chiba H, Sawada N, Yokozaki H:
Hypermethylation-modulated downregulation of claudin-7 expression
promotes the progression of colorectal carcinoma. Pathobiology 2008,
75:177-185.
25. Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, et al: A
complex of EpCAM, claudin-7, CD44 variant isoforms and tetraspanins
promotes colorectal cancer progression. Mol Cancer Res 2007, 5:553-567.
26. Obayashi T, Hayashi S, Shibaoka M, Saeki M, Ohta H, Kinoshita K:
COXPRESdb: a database of coexpressed gene networks in mammals.
Nucleic Acids Res 2008, 36:D77-D82.
27. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The
Norwegian Colorectal Cancer Prevention (NORCCAP) screening study:
baseline findings and implementations for clinical work-up in age
groups 50-64 years. Scand J Gastroenterol 2003, 38:635-642.
28. Johnson MR, Wang KS, Smith JB, Heslin MJ, Diasio RB: Quantitation of
dihydropyrimidine dehydrogenase expression by real-time reverse
transcription polymerase chain reaction. Analytical Biochemistry 2000,
278:175-184.
29. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, et al: Loss of
the tight junction protein claudin-7 correlates with histological grade in
both ductal carcinoma in situ and invasive ductal carcinoma of the
breast. Oncogene 2003, 22:2021-2033.
30. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T,
et al: Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the
polarity and increases the tumorigenicity of colorectal cancer cells.
Cancer Res 2008, 68:4258-4268.
31. Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C,
Alpert L, et al: Identification of genes associated with head and neck
carcinogenesis by cDNA microarray comparison between matched
primary normal epithelial and squamous carcinoma cells. Oncogene 2002,
21:2634-2640.
32. Hsueh C, Chang YS, Tseng NM, Liao CT, Hsueh S, Chang JH, et al:
Expression pattern and prognostic significance of claudins 1, 4, and 7 in
nasopharyngeal carcinoma. Hum Pathol 2010, 41:944-950.
33. Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N, et al:
Reduced expression of claudin-7 correlates with invasion and metastasis
in squamous cell carcinoma of the esophagus. Hum Pathol 2006,
37:569-577.
34. Sauer T, Pedersen MK, Ebeltoft K, Naess O: Reduced expression of Claudin-
7 in fine needle aspirates from breast carcinomas correlate with grading
and metastatic disease. Cytopathology 2005, 16:193-198.
35. Tokes AM, Kulka J, Paku S, Mathe M, Paska C, Lodi C, et al: The expression
of five different claudins in invasive breast carcinomas: comparison of
pT1pN1 and pT1pN0 tumors. Pathol Res Pract 2005, 201:537-544.
36. Rendon-Huerta E, Teresa F, Teresa GM, Xochitl GS, Georgina AF,
Veronica ZZ, et al: Distribution and expression pattern of claudins 6, 7,
and 9 in diffuse- and intestinal-type gastric adenocarcinomas.
J Gastrointest Cancer 2010, 41:52-59.
37. Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, et al:
Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol
Cancer 2008, 18:1262-1271.
38. Rosenthal R, Milatz S, Krug SM, Oelrich B, Schulzke JD, Amasheh S, et al:
Claudin-2, a component of the tight junction, forms a paracellular water
channel. J Cell Sci 2010, 123:1913-1921.
39. Aung PP, Mitani Y, Sanada Y, Nakayama H, Matsusaki K, Yasui W:
Differential expression of claudin-2 in normal human tissues and
gastrointestinal carcinomas. Virchows Arch 2006, 448:428-434.
40. Kinugasa T, Huo Q, Higashi D, Shibaguchi H, Kuroki M, Tanaka T, et al:
Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer.
Anticancer Res 2007, 27:3729-3734.
41. Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, et al:
Dysregulation of claudin-7 leads to loss of E-cadherin expression and
the increased invasion of esophageal squamous cell carcinoma cells. Am
J Pathol 2007, 170:709-721.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/65/prepub
doi:10.1186/1471-2407-11-65
Cite this article as: Bornholdt et al.: The level of claudin-7 is reduced as
an early event in colorectal carcinogenesis. BMC Cancer 2011 11:65.
Bornholdt et al. BMC Cancer 2011, 11:65
http://www.biomedcentral.com/1471-2407/11/65
Page 9 of 9